ClearPoint Neuro, Inc.

NasdaqCM:CLPT Stock Report

Market Cap: US$147.0m

ClearPoint Neuro Past Earnings Performance

Past criteria checks 0/6

ClearPoint Neuro's earnings have been declining at an average annual rate of -32%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 21% per year.

Key information

-32.0%

Earnings growth rate

-15.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate21.0%
Return on equity-104.3%
Net Margin-92.2%
Next Earnings Update07 May 2024

Recent past performance updates

Recent updates

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Apr 17
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Jan 03
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro: Continuous Great Execution

Sep 19

ClearPoint Neuro: Picks & Shovels Galore

Aug 19

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Aug 18
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

Jul 25

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

May 20

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Apr 25
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro: A Strong Recovery Play Once COVID Subsides

Mar 18

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Jan 19
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

Jan 14

ClearPoint Neuro: Becoming The Neurosurgical Platform Of Choice

Oct 01

ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company

Aug 06

Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?

Jul 19
Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?

Clearpoint Neuro (CLPT) Investor Presentation - Slideshow

May 28

Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

May 27
Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

May 13
US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

ClearPoint Neuro partners with D&K Engineering

May 10

ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Path To Profitability

Apr 16
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Path To Profitability

Revenue & Expenses Breakdown
Beta

How ClearPoint Neuro makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CLPT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2324-222412
30 Sep 2322-222312
30 Jun 2322-212212
31 Mar 2321-182111
31 Dec 2221-161911
30 Sep 2220-161811
30 Jun 2219-161811
31 Mar 2217-161611
31 Dec 2116-14159
30 Sep 2116-12148
30 Jun 2115-9137
31 Mar 2114-7115
31 Dec 2013-7115
30 Sep 2012-7104
30 Jun 2012-6103
31 Mar 2012-6103
31 Dec 1911-693
30 Sep 1910-583
30 Jun 199-582
31 Mar 198-682
31 Dec 187-682
30 Sep 187-782
30 Jun 187-782
31 Mar 187-783
31 Dec 177-783
30 Sep 177-783
30 Jun 177-883
31 Mar 176-883
31 Dec 166-883
30 Sep 166-883
30 Jun 165-582
31 Mar 165-782
31 Dec 155-882
30 Sep 154-992
30 Jun 153-1393
31 Mar 154-1193
31 Dec 144-583
30 Sep 144-483
30 Jun 144-473
31 Mar 143-473
31 Dec 134-773
30 Sep 135-463
30 Jun 135-463

Quality Earnings: CLPT is currently unprofitable.

Growing Profit Margin: CLPT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CLPT is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.

Accelerating Growth: Unable to compare CLPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLPT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).


Return on Equity

High ROE: CLPT has a negative Return on Equity (-104.33%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.